Cryoprecipitate was first used in the 1960s as a source of factor VIII (FVIII) for the treatment of bleeding in haemophilia A. Although still used in some countries for this purpose, its main use now is as a concentrated source of fibrinogen, commonly administered as part of major haemorrhage therapy for patients with uncontrolled bleeding. Fibrinogen is recognized as the first clotting protein to fall to clinically significant low levels during major haemorrhage, and there has been a recent explosion of interest around the potential importance of fibrinogen replacement therapy in this setting. This has led many to question the relative benefits of cryoprecipitate as compared to fibrinogen concentrate. This review will explore whether cryoprecipitate, in the era of specific factor concentrates, is an outmoded treatment. Cryoprecipitate is manufactured from frozen plasma after controlled thawing. It is not only a rich source of FVIII and fibrinogen but also contains von Willebrand Factor (VWF), FXIII and fibronectin. In UK, cryoprecipitate is available as single donor units or as pools of 5 units and requires thawing before transfusion. Variability in clotting factor levels in blood donors means that the fibrinogen concentration in cryoprecipitate may vary. With the exception of donor screening and viral testing at the time of donation, no viral reduction steps are taken during manufacture. Fibrinogen concentrate is an alternative concentrated source of fibrinogen but is not licensed in every country for acquired bleeding. It is a plasma-derived product manufactured from pooled plasma. Many view fibrinogen concentrate as a superior product to cryoprecipitate with reasons including: standardization of production-vials contain a known fibrinogen concentration; lyophilization making it easily portable and not requiring storage or thawing in blood bank; viral inactivation; a consideration for the UK is a likely lower risk for vCJD transmission. Gram for gram, fibrinogen concentrate is four times the cost of cryoprecipitate. The UK haemophilia centre doctors organisation (UKHCDO) recommends the use of single-factor agents above pooled blood components for replacement therapy in inherited bleeding conditions, where possible, for many of these reasons. But what about cryoprecipitate as therapy for acquired bleeding where patients develop a complex coagulopathy affecting multiple coagulation and fibrinolytic factors? Might cryoprecipitate therapy confer an advantage? Theoretically, higher concentrations of VWF, FVIII and FXIII might promote more rapid primary and secondary haemostasis. Clinical efficacy for the two products in observational studies and one RCT has been reported to be similar, where increases in fibrinogen blood levels are comparable. However, no study has yet been large enough to look at comparative clinical efficacy or indeed safety. In the era of single-factor concentrates, cryoprecipitate may seem outdated, but at present-in particular in relation to therapy for major haemorrhage-insufficient evidence is available which confirms or refutes it place in major haemorrhage therapy.
Introduction
Cryoprecipitate has been available for transfusion since 1964; initially as therapy for haemophilia A, then rapidly becoming first line treatment for von Willebrand's disease and heritable deficiencies of fibrinogen and FXIII [1] . With the advent of single-factor concentrate therapy the number of clinical indications for cryoprecipitate has reduced. It is recommended now for patients with acquired hypofibrinogenaemia only, most commonly as a result of major bleeding or disseminated intravascular coagulation (DIC). It is no longer recommended as first line therapy for heritable bleeding disorders if an alternative such as a single-factor concentrate or virally inactivated plasma products (solvent-detergent FFP) are available [2] . Indeed, much of Europe has phased out production of cryoprecipitate, instead favouring fibrinogen concentrates for all indications. In contrast, in the US, Australia, UK and Canada, fibrinogen concentrate is licensed only for heritable deficiencies.
Cryoprecipitate is a blood component, made by controlled thawing of frozen plasma at 1-6°C. Precipitation of high molecular weight proteins occurs, and the resultant product is a concentrated source of fibrinogen, FVIII, von Willebrand factor (VWF) and FXIII. It also contains fibronectin, small amounts of immunoglobulin and platelet microparticles [3] . Due to differences both in clotting factor levels in blood donors and in the manufacturing process, the content of cryoprecipitate varies (Table 1 ). In UK, standard cryoprecipitate is manufactured from single units of leucodepleted frozen plasma from male donors, and NHSBT standards stipulate a fibrinogen concentration of ≥140 mg/unit (and FVIII ≥70 iu/unit) in at least 75% units [4] . In UK, due to concerns about vCJD, methylene blue-treated cryoprecipitate is available for any person born after 1st January 1996-this product is specified to contain ≥140 mg/unit fibrinogen and ≥50 iu/ unit FVIII [4] .
In contrast, fibrinogen concentrate is a heat-treated, lyophilized fibrinogen powder made from pooled human plasma. It is a standardized product and has been available for use for over 50 years. Each vial contains between 900 and 1300 mg fibrinogen, 400 and 700 mg human albumin, and other constituents which aid the dissolution of the powdered fibrinogen into the solvent, most notably: 375-660 mg/l arginine hydrochloride [5] . • SD plasma
Pooled human plasma (30-60 000 donors) UK:
• standard-single male donors • MB treated (given in UK to patients born after 1/1/1996) USA:
• standard FFP 
Fibrinogen therapy for major bleeding
Both cryoprecipitate and fibrinogen concentrates are given during major haemorrhage to ameliorate low blood fibrinogen levels [6, 7] . Fibrinogen is critical for effective haemostasis. It is the precursor of fibrin and is an important mediator of platelet aggregation, via the platelet receptor GPIIb/IIIa. Once cleaved by thrombin, fibrinogen forms a network of insoluble polymerized fibrin strands that act as a 'mesh' to support the formation of a stable clot. Observational data support the important role of fibrinogen during bleeding and have shown that low fibrinogen levels are an independent predictor of mortality in trauma [8] , as well as bleeding in both trauma [9] and cardiac surgery [10] . Furthermore, a fibrinogen of 2 g/l or less in pregnant women has also been shown to accurately predict postpartum haemorrhage [11] . Despite it being known for over 20 years that fibrinogen is one of the first clotting factors to fall to clinically low levels [12] , the central importance of fibrinogen replacement for effective haemostasis in acquired bleeding has only recently been recognized. This is likely to be a major reason behind the reports of increased cryoprecipitate use (22% rise between 2011 and 2013 in UK), as well as increased fibrinogen concentrate use in Europe. A growing number of observational studies and randomized controlled trials have been published in the last 5-10 years exploring the effectiveness of fibrinogen replacement in major bleeding. A Cochrane review identified six small elective surgery trials of fibrinogen concentrate, all of low quality and the review reported no effect on mortality (2Á6% vs. 9Á5%, RR 0Á28, 95% CI: 0Á33-2Á33), but did show a clear reduction in the incidence of allogeneic transfusions (RR 0Á47, 95% CI: 0Á32-0Á72) [13] . A broader systematic review evaluated RCT (n = 7) and observational data (n = 23), again looking at fibrinogen concentrate as therapy for major bleeding [14] . The authors of this study concluded that there was only weak evidence from RCTs to support the use of fibrinogen concentrate, primarily in elective cardiac surgery, and that the general use of fibrinogen across all settings (cardiac, obstetric, trauma) was only supported by non-randomized studies which had serious methodological shortcomings.
As highlighted, to date most data evaluate fibrinogen concentrate alone and far fewer studies use cryoprecipitate. However, a recent systematic review explored clinical outcomes in studies using fibrinogen concentrate and cryoprecipitate in patients with bleeding [15] . Overall, in the four included studies (one RCT, three observational), there were no differences between either fibrinogen therapy in terms of bleeding, fibrinogen recovery, red blood cell (RBC) transfusions or thromboembolic (TE) complications (TE events were reported only in the RCT). Mortality data were not available, and the authors concluded that no recommendation could be made favouring one intervention over the other. The only other published RCT that has used cryoprecipitate [16] , evaluated its use in trauma haemorrhage [16] . This study showed that cryoprecipitate raised blood fibrinogen levels, was not associated with increased TE events and might have an effect on reducing mortality.
Beyond fibrinogen

Other haemostatic factors
The main reason for administering cryoprecipitate or fibrinogen concentrate during major haemorrhage is to replace the fibrinogen that has been lost. It is clear from observational studies that the recovery of fibrinogen using either cryoprecipitate or the most widely available fibrinogen concentrate (Riastap, CSL Behring) is similar. On average 4 g of administered fibrinogen raises the fibrinogen blood level by 1Á0 g/l [17] . However, cryoprecipitate (and indeed fibrinogen concentrate) contains much more than fibrinogen alone. It is unclear what role these additional coagulation factors play in overall haemostatic potential, or indeed whether the presence of anticoagulant factors (antithrombin) or antifibrinolytic factors (alpha-2 antiplasmin) play an additional role, perhaps by 'balancing' haemostatic and thrombotic processes.
Cryoprecipitate is rich in VWF, fibronectin, FVIII, FXIII and contains significant amounts of a2-antiplasmin and antithrombin. What role might these proteins play:
VWF:
VWF is important for primary haemostasis. It binds exposed subendothelial collagen and forms a 'haemostatic bridge' initiating the capture of platelets to sites of injury.
FVIII:
FVIII is a key coagulation protease, which is important for thrombin generation. FVIII is transported, and protected from breakdown, in plasma by VWF.
Fibronectin:
In mice, plasma fibronectin (pFn) has been shown to play a vital role in thrombus formation. pFn deposits rapidly at the site of vessel wall injury and promotes platelet aggregation through fibronectin-fibrin complexes and by so doing strengthens the developing fibrin clot [18] . Conversely, at the edges of a developing clot, pFn limits thrombus formation and prevents unregulated clot extension.
Factor XIII:
Factor XIII plays a critical role in secondary haemostasis, by cross-linking fibrin chains and stabilizing a forming thrombus. Importantly it also cross-links inhibitors of fibrinolysis (in particular a2-antiplasmin) to fibrin, preventing premature clot lysis and improving clot stability [19] . Normal resistance to lysis is seen when FXIII levels are above 0Á50 iu/ml (50%) [19] .
Alpha-2 antiplasmin:
Alpha-2 antiplasmin is a constituent of cryoprecipitate [20] and is the main coagulation protein that inhibits clot breakdown. Theoretically a2-AP may be an important by limiting fibrinolysis (as occurs in trauma haemorrhage, some forms of obstetric haemorrhage and DIC).
Observational data provide some data about what happens to these clotting factors in major bleeding. Following trauma, VWF levels are generally very high (thought to be augmented by endothelial cell activation and release of VWF from Weibel-Palade bodies) [21] . However, in patients with major haemorrhage following injury significantly lower VWF levels are reported (VWF levels: 224 iu/ml vs. 206 iu/ml, P = 0Á014) [21] . In addition to this, low FXIII levels are found in trauma patients with bleeding, compared to non-bleeding patients [21] . The importance of these changes, and indeed the haemostatic and clinical effect of replacing these factors together during major bleeding (e.g. by cryoprecipitate), is difficult to know and has not been studied. A recent trauma RCT compared plasma (FFP) therapy with factor concentrate therapy (which included fibrinogen concentrate, prothrombin complex concentrate and FXIII in varying amounts) for trauma patients with bleeding [22] . Due to the administration of all three factor concentrates in combination it has not been possible to delineate the effect of FXIII therapy alone.
The full range of coagulation factors (or their concentrations) that makes up fibrinogen concentrate is not known. In fact there are no recent publications detailing the constituents of cryoprecipitate, and therefore, the differential effects between these two therapies according to coagulation profiles can only be speculated. Clinical data show no overt differences in outcomes, and mechanistic studies are required to unpick whether any differences are seen in vivo at the haemostatic level.
Cost
The cost of the two products must not be ignored. On average, fibrinogen concentrate costs three-four times the amount of standard cryoprecipitate when compared per gram of fibrinogen (Table 1) . A recent cost analysis study concluded that even after taking into consideration a 28% wastage of cryoprecipitate and the cost of preparation of cryoprecipitate, fibrinogen concentrate was more expensive by a factor of two. The authors stated that either a 44% reduction in cost, or a change to a clinical outcome of importance, such as a significant reduction in ICU length of stay, was required to make fibrinogen concentrate economically competitive [23] .
Safety
Infection
One of the main safety concerns relating to standard cryoprecipitate transfusion is the risk of viral transmission, as it does not undergo pasteurization or viral inactivation. Efforts to pathogen reduce cryoprecipitate by treatment of plasma with riboflavin and UV light, amotosalen, and solvent detergent filtration have met with limited success as these methods generally lead to a 30% drop in fibrinogen [24] . Looking at data from the UK haemovigilance scheme, Serious Hazards of Transfusion (SHOT) (1996-2014), no cryoprecipitate-related cases of viral transmission were reported [25] until the 2015 SHOT report where one case of cryoprecipitate implicated HEV transmission was reported. Over this same time period, there were five cases of viral transmission with FFP (three HEV, one HIV and one HBV). Specific to the UK is the potential risk of vCJD. As yet, no pools of cryoprecipitate have been implicated in transmission of this prion.
Fibrinogen concentrate is virally inactivated, and therefore deemed to be safer than cryoprecipitate. Fibrinogen concentrate is made from pooled plasma-where many thousands of donations are pooled. This does increase donor number exposure for any recipients of this treatment, an important consideration for emerging pathogens.
Thromboembolic events
High fibrinogen levels are a risk factor for thrombosis. In postsurveillance monitoring, 1 thrombotic event per 23 300 doses of fibrinogen concentrate was reported from data covering a 27-year period [26] . Notably the majority of treatments in this report were given for heritable fibrinogen deficiency, where thrombotic risk profiles differ significantly from those of patients with major bleeding. Nevertheless, other studies that have evaluated fibrinogen concentrate therapy for major bleeding have raised no thrombotic or safety concerns [27] .
Data for cryoprecipitate are scanty. TE data are generally not collected in national haemovigilance databases.
Two RCTs have reported TE event data with cryoprecipitate (evaluating just over 100 patients) [16, 28] and neither has shown increased TE events with cryoprecipitate supplementation. In fact, in the trauma RCT, all TE events were reported in the comparator arm [16] .
Transfusion-related adverse events
One case of cryoprecipitate implicated transfusion-related acute lung injury (TRALI) has been reported since the inception of SHOT reporting in UK in 1996 [25] . In general, there are few transfusion-related adverse events attributable to cryoprecipitate, for example in the 2014, only one of the 43 acute transfusion reactions was attributed to cryoprecipitate, and cryoprecipitate was issued over 43 150 times that year.
Practical considerations
Much is made of the difference between the speed of reconstitution for fibrinogen concentrate compared with the thawing time for cryoprecipitate. Certainly, fibrinogen concentrate can be stored at the point of need, and therefore, transportation times are absent. However, on average it takes at least 10 min to reconstitute fibrinogen concentrate [29] . Once reconstituted, fibrinogen concentrate must be administered within 24 h. By way of contrast, cryoprecipitate takes 17-20 min to defrost. A small RCT study in trauma haemorrhage (CRYOSTAT1) evaluated the feasibility of administering cryoprecipitate to exsanguinating patients within 90 min of hospital admission [16] . The study confirmed feasibility and reported a median time of transfusion as 60 min (IQR: 57-76 min). In direct comparison, a similar trauma RCT which used fibrinogen concentrate confirmed the feasibility of administering this within 60 min, with an average time of administration of 51 min (IQR: 43-59 min) [30] -perhaps not as different as might be expected (although this study did reconstitute the concentrate in blood bank, adding transport times).
Once defrosted, cryoprecipitate has a shelf-life of 4 h, increasing its potential for wastage. Blood services have been addressing this particular issue by exploring the effects of extended post-thaw shelf-life, both to 24 h [31] and 72 h [32] . In both studies, no significant reductions in fibrinogen, FVIII, FXIII or VWF were found after storage at 20-24°C at either time point, and ROTEM parameters were similar at 72 h-suggesting maintenance of haemostatic potential [32] . Extended thaw times might, therefore, make cryoprecipitate more attractive for major haemorrhage therapy, reducing delivery time to the patient, and may make it quicker than concentrate administration.
Areas for future research
On the face of it there is much to recommend fibrinogen concentrate as a means to treat low fibrinogen levels-increased viral safety; higher and standardized concentrations; no blood group compatibility issues and the ability to keep the drug at the patient bedside. And indeed, for patients with inherited fibrinogen deficiency, where repeated prophylactic exposure to fibrinogen therapy is likely, where data confirm improved clinical outcomes when prophylaxis is given, and where long term viral safety of the prophylactic therapy is paramount, it makes sense to give concentrate.
However, the case for acquired hypofibrinogenaemia is not so clear cut. Data are scanty-and before we even consider which of these two sources of fibrinogen has the greater overall benefit-we need to determine whether outcomes after major bleeding are even improved using fibrinogen supplementation. And in addition, if fibrinogen is confirmed to be beneficial, we need to know what fibrinogen threshold we should be administering fibrinogen for greatest effect. It is only then, when these questions are answered, that attention can be turned to compare the two therapies and to look in greater detail at differential outcomes.
Several studies are currently open and will provide important results to inform future management. CRYO-STAT-2 (ISRCTN 14998314) is a large multicenter, international trauma trial evaluating whether 6 g of early fibrinogen replacement (three pools of cryoprecipitate) reduces mortality in adults with major trauma haemorrhage. It is expected to recruit just fewer than 1600 patients and will complete recruitment in 2020. A large (n = 1200) multicenter study will also open soon in Canada (FIBRES: NCT03037424) looking at the effect of fibrinogen concentrate in cardiac surgery, with red cell transfusion as the primary endpoint. These two large studies will provide robust information about clinical effectiveness of these two therapies. Two smaller RCTs are on-going comparing fibrinogen concentrate with cryoprecipitate; one in patients undergoing cardiopulmonary bypass (TOP-CLOT: NCT02540434) and one in trauma (FEISTY: NCT02745041). These studies will add to the knowledge base, providing important answers about differential benefits of either treatment.
Conclusions
There are, as yet, no clear clinical data that show that fibrinogen concentrate is superior to cryoprecipitate in any clinical setting. Infection risk and cost remain the two significant differences between these products which must be considered when treating patients. To address the uncertainties around fibrinogen supplementation, multicentre studies with large patient numbers must be conducted, ideally with mechanistic sub studies evaluating in vivo differences in haemostatic potential.
